Kristin Brooks01.28.21
Evozyne, LLC, a molecular engineering technology company, entered a strategic collaboration and license agreement with Takeda Pharmaceutical Co. Ltd. under which Evozyne's evolution-based protein design technology will be used to research and develop proteins that could be incorporated into next generation gene therapies for genetic disorders within inborn errors of metabolism and lysosomal storage disease areas.
Evozyne leverages advanced computational and machine learning methods in its evolution-based, data-driven engineering process that can be used to create synthetic proteins with new precision and efficiency for multiple applications. In partnership with Takeda, Evozyne will create novel protein sequences for advancement as gene therapies. Takeda has the option to obtain an exclusive license to develop and commercialize the novel protein sequences as part of its gene therapy program.
Evozyne is eligible to receive an upfront payment and additional research, development and regulatory milestones and royalties on sales of any commercial products resulting from the collaboration.
Evozyne leverages advanced computational and machine learning methods in its evolution-based, data-driven engineering process that can be used to create synthetic proteins with new precision and efficiency for multiple applications. In partnership with Takeda, Evozyne will create novel protein sequences for advancement as gene therapies. Takeda has the option to obtain an exclusive license to develop and commercialize the novel protein sequences as part of its gene therapy program.
Evozyne is eligible to receive an upfront payment and additional research, development and regulatory milestones and royalties on sales of any commercial products resulting from the collaboration.
